-
公开(公告)号：US11655295B2
公开(公告)日：2023-05-23
申请号：US16963067
申请日：2019-01-03
Inventor： Tongtong Xue , Qiang Li , Liang Xiao , Yuncheng Zheng , Dengnian Liu , Si Chen , Yan Hu , Lichun Wang , Jingyi Wang
IPC: C07K16/28 , A61K39/395 , A61P35/00
CPC classification number: C07K16/2803 , A61K39/39558 , A61P35/00
Abstract: The present invention relates to the field of treatment of diseases and immunology. Specifically, the present invention relates to an anti-LAG-3 antibody or an antigen-binding fragment thereof, nucleic acid molecules for encoding said antibody and fragment, and method for preparing said antibody and fragment. The anti-LAG-3 antibody or the antigen-binding fragment thereof according to the present invention has high specificity and high affinity to LAG-3, can effectively block the binding of LAG-3 to MHC II and/or FGL1, and can inhibit and/or block intracellular signaling mediated by LAG-3 binding to MHC II and/or FGL1. Therefore, the present invention further relates to a pharmaceutical composition comprising the antibody or the antigen-binding fragment thereof, and use of the pharmaceutical composition in the preparation of drugs. The drugs are used for improving the activity of immune cells and enhancing the immune response, or are used for preventing and/or treating tumors, infections or autoimmune diseases.
-
公开(公告)号：US11434235B2
公开(公告)日：2022-09-06
申请号：US16981430
申请日：2019-05-06
Inventor： Tianming Wang , Chengxi Yang , Jiaqiang Cai , Wei Liu , Baolei Zhang , Qiang Tian , Shuai Song , Hao Hu , Weibiao Han , Youqiang Li , Xing Chen , Lichun Wang , Jingyi Wang
IPC: C07D417/14 , A61K45/06
Abstract: Disclosed are a solid form of (E)-3-((R)-4-(((R)-6-(2-chloro-4-fluorophenyl)-5-(methoxycarbonyl)-2-(thiazol-2-yl)-3,6-dihydropyrimidin-4-yl)methyl)morpholin-2-yl)acrylic acid, a preparation method therefor, a pharmaceutical composition comprising same, and the use thereof in the preparation of drugs for preventing or treating viral diseases.
-
公开(公告)号：US10159662B2
公开(公告)日：2018-12-25
申请号：US15767508
申请日：2016-12-08
Inventor： Yinong Xie , Zejin You , Zhiwen Deng , Jun Zhu , Ao Wang , Yan Feng , Dong Long , Hong Zeng , Hongmei Song , Qijun Ye , Wei Qi , Donghai Su , Lichun Wang , Jingyi Wang
IPC: A61K31/437 , A61P19/02 , A61P29/00 , A61P35/00 , A61P37/00 , A61K39/00 , A61K31/343 , A61K38/17 , A61K31/519
Abstract: The present invention relates to an azetidine derivative for use as a Janus kinase (JAK) inhibitor, a drug composition comprising same, a preparation method therefor, and a use thereof in the treatment of JAK-related diseases comprising, for example, inflammatory diseases, autoimmune diseases, and cancers.
-
公开(公告)号：US11667629B2
公开(公告)日：2023-06-06
申请号：US16758232
申请日：2018-12-07
Inventor： Jinming Liu , Jiaqiang Cai , Yongyong Wu , Wei Yin , Lichun Wang , Jingyi Wang
IPC: C07D417/14 , C07D451/02 , C07D413/14 , B65D85/00
CPC classification number: C07D417/14 , B65D85/70 , C07D413/14 , C07D451/02
Abstract: The present invention generally relates to an isoxazole derivative, a preparation therefor, and a use thereof. In particular, the present invention provides a farnesoid X receptor (FXR) agonist compound, and a stereoisomer, a tautomer, a polymorph, a solvate (e.g., a hydrate), a pharmaceutically acceptable salt, an ester, a metabolite, and an N-oxide, and the chemically protected forms and prodrugs thereof. The present invention further provides a preparation method for the compound, an intermediate thereof, and a pharmaceutical composition and kit containing the same and used thereof for treating FXR-mediated diseases or conditions.
-
公开(公告)号：US11332457B2
公开(公告)日：2022-05-17
申请号：US16652274
申请日：2018-11-15
Inventor： Jiawang Zhu , Zhiquan Song , Dong Long , Lichun Wang , Jingyi Wang
IPC: C07D401/04 , A61P1/16 , C07D215/14 , C07D215/227 , C07D215/36 , C07D215/38 , C07D333/56 , C07D413/04
Abstract: The invention relates to an aromatic compound, pharmaceutical composition comprising the same, and a method for preparing the compound and an intermediate thereof. The invention also relates to use of the compound for the manufacture of a medicament for the prevention or treatment of a PPAR-related disease.
-
Patent Agency Ranking
公开(公告)号：US11292785B2
公开(公告)日：2022-04-05
申请号：US16959691
申请日：2019-01-18
Inventor： Shuai Song , Qiang Tian , Yongyong Wu , Mingliang Zhao , Chaolei Wang , Jiaqiang Cai , Lichun Wang , Jingyi Wang
IPC: C07D403/12 , A61P1/16
Abstract: Related is a nitrogen-containing benzoheterocycle compound containing a carboxylic acid group as shown in general formula (I), or a stereoisomer or pharmaceutically acceptable salt thereof. The compound has excellent pharmacokinetic properties and extremely remarkable liver targeting properties, and a pharmaceutical composition comprising the same may be used as a CCR antagonist, in particular a CCR2 and/or CCR5 antagonist and can be used in mediated disease, including, but not limited to, nonalcoholic fatty liver disease (NAFLD) or the like.
-
公开(公告)号：US10787477B2
公开(公告)日：2020-09-29
申请号：US16343846
申请日：2017-12-15
Inventor： Chengxi Yang , Yufeng Liang , Jiangfeng Zhou , Jianhua Ge , Qiang Tian , Mingliang Zhao , Hong Zeng , Fulu Zhao , Jianfeng Han , Lichun Wang , Jingyi Wang
IPC: C07H19/10 , C07H1/06 , A61P35/00 , A61P31/12 , A61K31/7068
Abstract: The present invention relates to a solid form of a compound of Formula (I), a method for preparing the solid form, a pharmaceutical composition comprising the solid form, and the use of the solid form in the treatment of a disease involving abnormal cell proliferation or a viral infectious disease.
-
公开(公告)号：US10696669B2
公开(公告)日：2020-06-30
申请号：US16334237
申请日：2017-11-09
Inventor： Shuai Song , Jiaqiang Cai , Qiang Tian , Hong Zeng , Hongmei Song , Hanwen Deng , Zujian Tang , Xiaofan Duan , Rongrong Long , Yao Liu , Lichun Wang , Jingyi Wang
IPC: C07D417/14 , C07D413/14 , C07D403/14 , C07D401/14 , C07D417/04 , A61P31/16 , A61P31/22 , A61P31/12 , A61K31/506 , A61K9/00
Abstract: The present invention relates to a dihydropyrimidine compound having an antiviral activity, a pharmaceutical composition comprising same, a preparation method therefor and the uses thereof in the prevention or treatment of viral diseases including, but not limited to, Hepatitis A, Hepatitis B, Hepatitis C, influenza, herpes and acquired immunodeficiency syndrome (AIDS).
-
公开(公告)号：US10465014B2
公开(公告)日：2019-11-05
申请号：US15745230
申请日：2017-03-02
Inventor： Baiyong Li , Tongtong Xue , Yu Xia , Zhongmin Maxwell Wang , Liang Xiao , Lichun Wang , Jingyi Wang
IPC: C07K16/46 , A61K39/395 , C07K14/705 , C07K16/28 , A61K47/68 , A61P35/02
Abstract: The present invention belongs to the field of tumor therapy and molecular immunology, and relates to a PDL-1 antibody, a pharmaceutical composition thereof and use thereof. In particular, the present invention relates to a PDL-1 monoclonal antibody or an antigen-binding fragment thereof, wherein the monoclonal antibody has a heavy chain variable region comprising CDRs as set forth in SEQ ID NOs: 15-17; and/or has a light chain variable region comprising CDRs as set forth in SEQ ID NOs: 18-20. The monoclonal antibody of the present invention can bind to PDL-1 specifically, and specifically remove immunosuppressive function of PDL-1 and activate T lymphocytes.
-
公开(公告)号：US11541049B2
公开(公告)日：2023-01-03
申请号：US16965450
申请日：2019-03-18
Inventor： Yongyong Wu , Jiaqiang Cai , Guangchao Zhang , Shuangshuang Duan , Chaolei Wang , Lichun Wang , Jingyi Wang
IPC: C07D403/14 , A61K31/496 , A61P7/02 , A61K31/4725 , A61K45/06 , C07D401/14 , C07D413/14 , C07D401/10
Abstract: Provided are tetrahydroisoquinoline derivatives, the preparation and use thereof. More specifically, provided are the tetrahydroisoquinoline derivatives or a pharmaceutically acceptable salt, ester, stereoisomer, tautomer, polymorph, solvate, isotopically labeled compound, metabolite or prodrug thereof. Further provided are a preparation process of the compound, the intermediates, a pharmaceutical composition comprising the compound and the use thereof in the treatment or prevention of a thromboembolic disorder.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.021 seconds)
